公开(公告)号：US11246873B2

公开(公告)日：2022-02-15

申请号：US16843832

申请日：2020-04-08

申请人： The Scripps Research Institute ,  Novartis AG

发明人： Peter Schultz ,  Luke Lairson ,  Vishal Deshmukh ,  Costas Lyssiotis

IPC分类号： A61K31/44 ,  A61K31/445 ,  A61K31/40 ,  A61K31/35 ,  A61K31/24 ,  A61K31/135 ,  A61K38/00 ,  A61K31/5415 ,  A61K31/439 ,  A61K31/138 ,  A61K31/137 ,  A61K38/21 ,  A61K39/395 ,  A61K31/216 ,  A61K31/46 ,  A61K31/495

摘要： The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

公开(公告)号：US20220031973A1

公开(公告)日：2022-02-03

申请号：US17499488

申请日：2021-10-12

申请人： Novartis AG

发明人： Peter Matthewson ,  Laure Mahe

IPC分类号： A61M15/00

摘要： A method for generating a flow profile of an inhalation device is described. The method comprises the step of measuring acoustic emissions induced by inhalation flow through the inhalation device. The method further comprises the step of detecting peak frequencies in the measured acoustic emissions and generating a flow profile based on the detected peak frequencies. A corresponding device is also described.

公开(公告)号：US20220031657A1

公开(公告)日：2022-02-03

申请号：US17502986

申请日：2021-10-15

申请人： NOVARTIS AG

发明人： Tinya ABRAMS ,  Larry Alexander GAITHER

IPC分类号： A61K31/381 ,  A61K9/00 ,  A61P35/00 ,  A61K31/519

摘要： The present invention relates to a pharmaceutical combination comprising LSZ102 and ribociclib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with CDK4/6 inhibition is beneficial in, for example, the treatment of cancers.

公开(公告)号：US11235316B2

公开(公告)日：2022-02-01

申请号：US16316709

申请日：2017-07-10

申请人： Novartis AG

发明人： Fabrice Gallou ,  Pengfei Guo ,  Jianguang Zhou ,  Michael Parmentier

IPC分类号： C07C211/04 ,  B01J31/22 ,  B01J13/00 ,  B01J31/02 ,  B01J31/24 ,  C08L71/00 ,  B01J31/18 ,  C07C231/02 ,  C07C233/73

摘要： The present invention is directed to reaction mixtures comprising a water-surfactant mixture, wherein the catalyst comprises a compound with solubilizing groups. This technology improves the solubility of the reaction components in the water-surfactant mixture and thereby, greatly increases the productivity and selectivity of the chemical reaction.

公开(公告)号：US20220025032A1

公开(公告)日：2022-01-27

申请号：US17375860

申请日：2021-07-14

申请人： NOVARTIS AG

发明人： Chad Eric BIGELOW ,  Ana Maria CARRION ,  James Edgar CHASTAIN ,  Kirk Lee CLARK ,  Bijan Alexandre ETEMAD-GILBERTSON ,  Joy Gispati GHOSH ,  Shawn Michael HANKS ,  Nicole HAUBST ,  Ganesh Rajan IYER ,  Nina MOKER ,  Andrew Anh NGUYEN ,  Stephen Hendrick POOR ,  Yubin QIU ,  Nalini Velamur RANGASWAMY ,  Michael STEFANIDAKIS ,  Engin TOKSOZ ,  Michael Zbigniew TWAROG

IPC分类号： C07K16/22 ,  C07K16/46 ,  A61P27/02

摘要： The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.

公开(公告)号：US20220016103A1

公开(公告)日：2022-01-20

申请号：US17376483

申请日：2021-07-15

申请人： Novartis AG

发明人： Irina BALTCHEVA ,  Peter END ,  Julie Marie-Pomme Gabrielle MILOJEVIC

IPC分类号： A61K31/454 ,  A61K9/00 ,  A61P7/06

摘要： Described herein are methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with the Factor B inhibitor LNP023 or a pharmaceutically acceptable salt thereof, e.g. LNP023 hydrochloride.

公开(公告)号：US11224539B2

公开(公告)日：2022-01-18

申请号：US16006506

申请日：2018-06-12

申请人： Novartis AG

发明人： Reto Grueebler

IPC分类号： A61B17/29 ,  A61F9/007 ,  A61B17/30 ,  A61B17/00

摘要： Surgical instruments for use in membrane peeling in treatments of different macular surface diseases are disclosed herein. Membrane forceps may include a forceps extension and forceps jaws extending from a distal termination of the forceps extension. The forceps jaws may include a first jaw and a second jaw. Each of the first jaw and the second jaw may include a gripping tip that abuts one another when the forceps jaws are in a closed configuration so as to grasp a membrane The first jaw and the second jaw may each include a coating at a distal end of the forceps jaws configured to increase a frictional force between the membrane and the forceps jaws.

公开(公告)号：US20210398636A1

公开(公告)日：2021-12-23

申请号：US17401770

申请日：2021-08-13

申请人： Novartis AG

发明人： Dominik Ziegler ,  Manfred Mueller

IPC分类号： G16H20/13 ,  G16H40/63 ,  G16H40/67 ,  G06F21/30 ,  G06F21/35

摘要： According to one embodiment, a system includes a medical device configured to provide a function to a user, communicate via a wireless communication channel with one or more other devices, and send a signal to shift a medical device application from a locked state to an unlocked state. The system also includes a computing device having wireless communication channels and a processor and logic integrated with and/or executable by the processor. The logic is configured to cause the computing device to communicate with the medical device, execute the medical device application, and shift from the locked state to the unlocked state in response to receiving the signal from the medical device. Core functionality of the medical device application is disabled when the medical device application is in the locked state, and some functionality applicable to the medical device is enabled when the medical device application is in the unlocked state.

公开(公告)号：US20210386763A1

公开(公告)日：2021-12-16

申请号：US17415985

申请日：2019-12-18

申请人： NOVARTIS AG

发明人： Nelson GUERREIRO ,  Ensar HALILOVIC ,  Astrid JULLION ,  Christophe MEILLE ,  Youzhen WANG

IPC分类号： A61K31/635 ,  A61K31/506 ,  A61K45/06 ,  A61P35/02

摘要： The present invention relates to the combination of the HDM2-p53 interaction inhibitor drug (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one [HDM201] and the BCL2 inhibitor 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(3-nitro-4-{[(oxan-4yl)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide [venetoclax]. The present invention further relates to the use of said combination in the treatment of cancer, in particular hematological tumors. The present invention further relates to dose and dosing regimen related to this combination cancer treatment.

公开(公告)号：US20210379062A1

公开(公告)日：2021-12-09

申请号：US17284011

申请日：2019-10-10

申请人： Novartis AG

发明人： Donald Johns ,  Judit Sovago

IPC分类号： A61K31/501 ,  A61K31/198 ,  A61K31/4745 ,  A61K31/4045 ,  A61K31/277 ,  A61K31/165 ,  A61K31/426 ,  A61P25/26

摘要： The invention relates to the use of Compound (I), as defined herein, or pharmaceutically acceptable salt thereof, in the treatment of excessive daytime sleepiness associated with Parkinson's disease.